The 2C-T-x compounds are a chemically defined subset of the 2C phenethylamine family, distinguished by a thioalkyl substituent at the 4-position of the 2,5-dimethoxyphenethylamine scaffold.[1] Membership is structural rather than functional: every member shares the same backbone, with the suffix ("T-2", "T-7", "T-21") denoting the specific thioalkyl chain appended at that position.
The class is small and tightly grouped. It comprises 2C-T with a methylthio group, 2C-T-2 with an ethylthio chain, 2C-T-7 with a propylthio chain (the most extensively documented member, distributed under the name "Blue Mystic"), and 2C-T-21 with a fluoroethylthio chain.[2] Despite differences in chain length and composition, the members converge on a broadly similar psychedelic profile.
Across the exposure range, the class produces perceptual brightening and mild sensory enhancement at low doses, full visual and cognitive psychedelic effects at moderate doses, and pronounced somatic activation alongside hallucination at higher doses.[2] Use is essentially non-medical, occurring in recreational and self-experimental contexts; the compounds have no current clinical role, and 2C-T-7 in particular has been associated with documented fatalities and emergency regulatory action.
Pharmacology
The 2C-T-x compounds act primarily through partial agonism at the serotonin 5-HT2A receptor, the shared mechanism of classical psychedelics.[3] Activity at 5-HT2C and weaker engagement of 5-HT2B are also characteristic across the class, while interaction with monoamine transporters is minimal — a profile that distinguishes the class pharmacologically from amphetamines and from MDMA.[3]
| Target | Class-wide activity | Functional role |
|---|---|---|
| 5-HT2A receptor | Potent partial agonist | Primary driver of the psychedelic experience |
| 5-HT2C receptor | Partial agonist | Contributes to subjective effects and mood modulation |
| 5-HT2B receptor | Weaker partial agonist; varies by chain composition | Off-target activity of cardiovascular interest |
| Monoamine oxidase (MAO-A and MAO-B) | Inhibitor; potency varies by member | Raises monoamine concentrations and underlies combination risk |
| Monoamine transporters (SERT, DAT, NET) | Minimal activity | Separates the class pharmacologically from releasing agents and stimulants |
The receptor profile sets the experiential character, but the class-specific safety feature is the second column: 2C-T-x compounds inhibit MAO-A and MAO-B at concentrations relevant to recreational doses, with one in vitro survey concluding that "a pharmacological contribution of MAO inhibition cannot be excluded".[4]
Combined with 5-HT2A partial agonism, that dual action is the mechanistic basis for the heightened serotonin-syndrome risk seen when these compounds are taken alongside other serotonergic drugs.
Substances
| Member | 4-position chain | Role / distinctive feature |
|---|---|---|
| 2C-T | methylthio (—SCH3) | Parent compound and shortest chain; characterized primarily in PiHKAL with sparse modern documentation |
| 2C-T-2 | ethylthio (—SC2H5) | Qualitatively similar profile to 2C-T-7; less potent by weight; minimal modern clinical case literature |
| 2C-T-7 | propylthio (—SC3H7) | Most extensively documented member; distributed as "Blue Mystic"; DEA emergency-scheduled in 2002 following documented deaths |
| 2C-T-21 | fluoroethylthio (—SCH2CH2F) | Fluorinated sidechain; sparser documentation; Shulgin described it as more energizing than overtly psychedelic at some doses |
The four members share the same backbone and produce qualitatively similar experiences, differing principally in potency, duration, and the balance of somatic and perceptual effects each tends to produce.
Subjective Effects
The class produces an experiential trajectory that scales with exposure and is broadly conserved across members, with Shulgin's PiHKAL providing the most extensive subjective record.[2]
| Exposure | Characteristic effects |
|---|---|
| Low | Perceptual brightening, color saturation, mild sensory enhancement, mood elevation, and a wakeful, alert quality |
| Moderate | Open- and closed-eye visual phenomena, altered time perception, pattern enhancement, and emotionally amplified cognition; entactogenic warmth in some accounts, particularly for 2C-T-7 and 2C-T-2 |
| High | Pronounced visual hallucination, thought loops, and disorientation, with significant somatic activation including muscle tension, jaw clenching, nausea, tachycardia, and elevated blood pressure |
Relative to many other psychedelics, 2C-T-x experiences are long in duration, with slower onset than tryptamines. Cardiovascular stimulation deepens alongside perceptual intensity as exposure rises, which means the same axis that drives the sought-after experience also drives the somatic and serotonergic risks — the margin between an intense psychedelic experience and a medically significant adverse event narrows at the upper end of the dose range.
Safety
Risk profile
The defining acute danger of the class is serotonin toxicity in combination with other serotonergic agents. The 2C-T-x compounds combine 5-HT2A partial agonism with measurable inhibition of monoamine oxidase, and co-administration with MDMA, SSRIs, SNRIs, other MAOIs, or amphetamine-class stimulants substantially raises the risk of serotonin syndrome — a life-threatening cascade of hyperthermia, autonomic instability, and neuromuscular hyperexcitability.[4][5]
Clinical reviews of 2C-series presentations describe two overlapping toxicity syndromes — serotonergic and sympathomimetic — with common features including hallucination, agitation, hypertension, tachycardia, seizures, and hyperthermia, and an excited-delirium presentation consistent across reported deaths.[5] Several deaths involving 2C-T-7 were documented in the early 2000s, the majority involving co-ingestion with MDMA.[6] These fatalities were the explicit basis for the DEA's 2002 emergency scheduling of 2C-T-7.
Route matters. Insufflation has been disproportionately represented in the serious case literature, partly because onset kinetics by that route can produce accidental overshoot. Treatment of acute toxicity is primarily supportive, with immediate intervention required for hyperthermia, seizure activity, and excited delirium.[5]
Tolerance & dependence
Tolerance to the psychedelic effects of 2C-T-x compounds develops rapidly with repeat dosing, primarily through 5-HT2A receptor downregulation.[7] Cross-tolerance is essentially complete within the class and extends to other 5-HT2A psychedelics, including tryptamine psychedelics: once tolerance is established to one classical psychedelic, the expected effects of others are correspondingly reduced.[7] Tolerance typically resolves over roughly a week of abstinence.
Physical dependence and a withdrawal syndrome of the kind seen with alcohol, benzodiazepines, or opioids have not been documented for the class.[5] The rapid tolerance is itself a functional barrier to daily-use patterns — re-dosing the next day produces markedly attenuated effects, which discourages the consumption pattern associated with physiological dependence syndromes.
Recovery
Recovery from an uncomplicated acute exposure is typically complete and requires no specific intervention beyond observation and a safe setting. Cases involving hyperthermia, seizures, or serotonin syndrome carry an organ-injury risk if not treated promptly; if any of these signs appear after exposure, treat the situation as a medical emergency and seek immediate care or contact a poison-control service. For ongoing concerns about use patterns, a clinician familiar with psychedelic harm reduction can provide structured guidance.Recovery resources, crisis lines, and support pathways → View all
Members
references
- [1]^Nichols, D.E. and Shulgin, A.T. (1976) Sulfur analogs of psychotomimetic amines — Journal of Pharmaceutical Sciences doi:10.1002/jps.2600651040
- [2]
- [3]^abLuethi D, Trachsel D, Hoener MC, Liechti ME (2018) Monoamine receptor interaction profiles of 4-thio-substituted phenethylamines (2C-T drugs) — Neuropharmacology doi:10.1016/j.neuropharm.2017.07.012
- [4]^abWagmann L, Brandt SD, Stratford A, Maurer HH, Meyer MR (2019) Interactions of phenethylamine-derived psychoactive substances of the 2C-series with human monoamine oxidases — Drug Testing and Analysis doi:10.1002/dta.2494
- [5]^abcdDean BV, Stellpflug SJ, Burnett A, Engebretsen KM (2013) 2C or Not 2C: Phenethylamine Designer Drug Review — Journal of Medical Toxicology doi:10.1007/s13181-013-0295-x
- [6]^Schifano, F. and Deluca, P. and Agosti, L. and Martinotti, G. and Corkery, J.M. and The Psychonaut 2002 Research Group (2005) New trends in the cyber and street market of recreational drugs? The case of 2C-T-7 ('Blue Mystic') — Journal of Psychopharmacology doi:10.1177/0269881105056660